Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Jun 7, 2022
Dr. Hernan Bazan is the CEO and Co-Founder of South Rampart Pharma and focuses on finding a new way to treat acute and chronic pain with a drug that has no expectation for abuse and is not toxic to the liver, kidneys, or cardiovascular system.
Hernan explains, "This is a tremendous unmet need in that there really has been no innovation in the pain space for over 50 years. Tylenol itself, acetaminophen, Tylenol was born in the '40s and the early '50s and worked by actually someone that was at the NIH that came to visit us a few times, a very well renowned neuroscientist. And he really discovered it incidentally, looking for another pathway, but we won't go into that. And that was adopted by McNeil Laboratories, and then eventually Johnson & Johnson."
"And then, in the '60s and '70s, non-steroidals, non NSAIDs, were marketed as Advil and ibuprofen, and a bunch of NSAIDs were derived. And these are very good medicines for preventing inflammation and treating pain in the short term. The challenge with both of these classes of pain meds is that they have risks."
"And then the third class, obviously, everybody knows about opioids and how they were marketed in the '90s."
@SR_Pharma #Pain #AcutePain #Analgesic #Acetaminophen #Opioid #NSAID #Nontoxic #NonOpioid #NewOrleans
